Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-18T20:50:57.914Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages

Published online by Cambridge University Press:  16 April 2020

David Misdrahi ,
Marie Tournier ,
Tiphaine Droulout ,
Adeline Grolleau ,
Karine Titier ,
Mathieu Molimard  and
Helene Verdoux
David Misdrahi*
Affiliation:
Pôle 347 de Psychiatrie Adulte, Centre Hospitalier Charles Perrens, 121 rue de la Béchade, 33076Bordeaux Cedex, France
Marie Tournier
Affiliation:
INSERM U657, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076Bordeaux Cedex, France Service Universitaire de Psychiatrie, Centre Hospitalier Charles Perrens, 121 rue de la Béchade, 33076Bordeaux Cedex, France
Tiphaine Droulout
Affiliation:
Service Universitaire de Psychiatrie, Centre Hospitalier Charles Perrens, 121 rue de la Béchade, 33076Bordeaux Cedex, France
Adeline Grolleau
Affiliation:
INSERM U657, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076Bordeaux Cedex, France
Karine Titier
Affiliation:
INSERM U657, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076Bordeaux Cedex, France
Mathieu Molimard
Affiliation:
INSERM U657, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076Bordeaux Cedex, France
Helene Verdoux
Affiliation:
INSERM U657, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076Bordeaux Cedex, France Service Universitaire de Psychiatrie, Centre Hospitalier Charles Perrens, 121 rue de la Béchade, 33076Bordeaux Cedex, France
*
*Corresponding author. Pôle de Psychiatrie adulte, Hôpital Charles Perrens, 121 rue de la Béchade, 33076 Bordeaux Cedex, France. Tel.: +33 5 56 56 34 50; fax: +33 5 56 56 35 46. E-mail address: [email protected] (D. Misdrahi).
Get access

Abstract

Objective

To investigate whether measurement of plasma levels can predict tolerance to oxcarbazepine (OXC).

Methods

We reviewed medical records to identify all inpatients consecutively treated by OXC at the University Department of Psychiatry in Bordeaux. Adverse effects were rated before treatment onset, at day 3, then every week and at discharge or at discontinuation. Residual hydroxy-OXC concentrations were measured on blood samples at the same periods.

Results

OXC was prescribed to 20 patients with bipolar (n = 18) or schizoaffective bipolar-type disorder (n = 2). Reported side effects were transient and occurred mostly at the beginning of the treatment. Three patients stopped OXC because of severe cutaneous side effects. Residual hydroxy-OXC plasma levels were similar in patients with or without occurrence of side effects at all times of assessment.

Conclusion

Our data suggest that the occurrence of severe side-effects is relatively high with OXC. Measurement of plasma OXC levels does not appear to be of interest in clinical practice since plasma concentrations are not predictive of the occurrence of side effects.

Keywords

OxcarbazepineBipolar disorderAnticonvulsants
Type
Original article
Information
European Psychiatry , Volume 23 , Issue 6 , September 2008 , pp. 409 - 412
Copyright
Copyright © Elsevier Masson SAS 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association, Diagnostic and statistical manual of mental disorders 4th ed. 1994 American Psychiatric Press WashingtonGoogle Scholar
American Psychiatric Association (APA) Practice guideline for the treatment of patients with bipolar disorder (revision) Am J Psychiatry. 159 2002 1–50Google Scholar
Bech, P.Rafaelsen, O.J.Kramp, P.Bolwig, T.G.The mania rating scale: scale construction and inter-observer agreement Neuropharmacology. 17 1978 430–431CrossRefGoogle ScholarPubMed
Benedetti, A.Lattanzi, L.Pini, S.Musetti, L.Dell'Osso, L.Cassano, G.B.Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode J Affect Disord. 79 2004 273–277CrossRefGoogle ScholarPubMed
Centorrino, F.Albert, M.J.Berry, J.M.Kelleher, J.P.Fellman, V.Line, G.et al.Oxcarbazepine: clinical experience with hospitalized psychiatric patients Bipolar Disord. 5 2003 370–374CrossRefGoogle ScholarPubMed
Emrich, H.M.Studies with oxcarbazepine (Trileptal) in acute mania Int Clin Psychopharmacol. 5 1990 83–88Google Scholar
Ghaemi, S.N.Berv, D.A.Klugman, J.Rosenquist, K.J.Hsu, D.J.Oxcarbazepine treatment of bipolar disorder J Clin Psychiatry. 64 2003 943–945CrossRefGoogle ScholarPubMed
Hellewell, J.S.Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability J Affect Disord. 72 Suppl. 1 2002 S23–S34CrossRefGoogle ScholarPubMed
Hummel, B.Walden, J.Stampfer, R.Dittmann, S.Amann, B.Sterr, A.et al.Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on–off–on design Bipolar Disord. 4 2002 412–417CrossRefGoogle Scholar
Johannessen, S.I.Battino, D.Berry, D.J.Bialer, M.Kramer, G.Tomson, T.et al.Therapeutic drug monitoring of the newer antiepileptic drugs Ther Drug Monit. 25 2003 347–363CrossRefGoogle ScholarPubMed
Lingjaerde, O.Ahlfors, U.G.Bech, P.Dencker, S.J.Elgen, K.The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side-effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl. 334 1987 1–100CrossRefGoogle Scholar
Lloyd, P.Flesch, G.Dieterle, W.Clinical pharmacology and pharmacokinetics of oxcarbazepine Epilepsia. 35 Suppl. 3 1994 S10–S13CrossRefGoogle ScholarPubMed
Montgomery, S.A.Asberg, M.A new depression scale designed to be sensitive to change Br J Psychiatry. 134 1979 382–389CrossRefGoogle ScholarPubMed
Pratoomsri, W.Yatham, L.N.Bond, D.J.Lam, R.W.Sohn, C.H.Oxcarbazepine in the treatment of bipolar disorder: a review Can J Psychiatry. 51 2006 540–545CrossRefGoogle ScholarPubMed
Pratoomsri, W.Yatham, L.N.Sohn, C.H.Solomons, K.Lam, R.W.Oxcarbazepine add-on in the treatment of refractory bipolar disorder Bipolar Disord. 7 Suppl. 5 2005 37–42CrossRefGoogle ScholarPubMed
Stata Corporation, Stata statistical software: release 8.0, user's guide 2005 Stata Press College StationGoogle Scholar
Suppes, T.Dennehy, E.B.Hirschfeld, R.M.Altshuler, L.L.Bowden, C.L.Calabrese, J.R.et al.The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder J Clin Psychiatry. 66 2005 870–886CrossRefGoogle ScholarPubMed
Wang, P.W.Ketter, T.A.Pharmacokinetics of mood stabilizers and new anticonvulsants Psychopharmacol Bull. 36 2002 44–66Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.